Dermasensor Inc. received CE mark approval for its handheld skin cancer detection device using spectroscopy and AI to test suspicious skin lesions for cancer in real time at the point of care. The device is designed to help qualified healthcare professionals decide whether suspicious skin lesions need further investigation. With skin cancer rates rising, the Dermasensor joins several other AI-based tools entering the European market to help with the analysis of suspicious lesions.
Replimune Group Inc. received another complete response letter (CRL) from the U.S. FDA for immunotherapy vusolimogene oderparepvec to treat advanced melanoma, sending shares plunging by more than 19% on the April 10 PDUFA date.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, arising from abnormal proliferation of epidermal keratinocytes due to chronic UV exposure. While highly curable (>90%) with surgical excision when detected early, it carries a significant risk of local invasion and metastasis if left untreated.
Almirall SA has nominated LAD-116 as a novel therapy targeting non-melanoma skin cancer for further development in IND-enabling studies. LAD-116 is based on collaborator Etherna Immunotherapies NV’s intratumoral mRNA/lipid nanoparticle (LNP) platform.
Shenzhen Targetrx Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to Raf kinase B (V600E mutant)-targeting moiety through linker reported to be useful for the treatment of cancer.
Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an EGFR (HER1; erbB1) mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
Sunrise Oncology (Hong Kong) Ltd. has identified molecular glues acting as phosphodiesterase PDE3A/SLFN12 interaction inducers reported to be useful for the treatment of cancer.
Aurigene Oncology Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase protein binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) binding moieties through a linker reported to be useful for the treatment of cancer.
While immunotherapy targeting PD-1 or its ligand PD-L1 has transformed cancer treatment by overcoming T-cell exhaustion, only a minority of patients achieves durable responses after treatment.
Oncolytic viruses are being actively explored as cancer therapies because they preferentially infect tumor cells and cause their lysis. At the same time, the viruses can accommodate transgenes that can stimulate anti-cancer responses in the local tumor microenvironment.
